Researchers have identified two experimental medications that may be able to promote myelin repair in people with MS, a study ...

Optic neuropathies including glaucoma, traumatic injury, ischemic damage, and optic neuritis, are the leading causes of irreversible blindness ...

In experiments in mouse tissues and human cells, researchers say they have found that removing a membrane that lines the back of the eye may improve the success rate for regrowing nerve cells damaged ...

TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a ...

NurExone Biologic Inc. has reported promising preclinical results for its drug ExoPTEN, which shows potential in repairing optic nerve damage and restoring vision, particularly for conditions like ...

A research team from the Medical University of Vienna and the Medical University of Graz has discovered a previously unknown ...

Detailed price information for Nurexone Biologic Inc (NRX-X) from The Globe and Mail including charting and trades.

A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...

NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ...

Each year thousands of patients face life-long losses in sensation and motor function from spinal cord injury and related conditions in which axons are badly damaged or severed. New research in mice ...